TechSeeker Profile

Centocor Inc (AKA: Centocor Ortho Biotech Inc)
Profile last edited on: 3/19/14

Novel therapeutics for cancer and infectious diseases
TS Type
Small Corp
Status
Acquired
Year Founded
1979
Last Involved Year
2019

Key People / Management

Location Information

800 Ridgeview Road
Horsham, PA 19044
   (215) 325-4473
   www.centocor.com

Public Profile

A publicly traded firm before becoming SBIR involved, in October 1999, Centocor was merged into Johnson & Johnson with the firm assuming wholly owned subsidiary status and renamed Janssen Biotech and ceased trading. It is interesting that the firm, renamed Centocor Biologics was sold by J&J in November 2010. Centocor makes therapeutic and diagnostic drugs for cancer, cardiovascular problems, and other diseases. Centocor's products, developed primarily through monoclonal antibody technology, help physicians deliver innovative treatments to improve human health and restore patients' quality of life. When J&J acquired Egea Biosciences in 2004, it was in fact an acquisition by and for Centocor.

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Headquartered
USA
Employment
375
Revenue
N/A
Public/Private
Publicly Traded
Stock Info
NASDAQ : CNTO
Received SBIR $$
Yes